BJDX Insider Trading Activity and SEC Form 4 Filings
BJDX insider trading summary
No open-market insider purchases or sales of Bluejay Diagnostics, Inc. (BJDX) have been reported on SEC Form 4 in the past 12 months.
Latest BJDX insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Dec 13, 2023 | Indranil Dey | President and CEO | Buy | $2K (500 @ $3.27) |
| Dec 13, 2023 | Svetlana Dey | Director | Buy | $2K (500 @ $3.07) |
| Aug 26, 2022 | Kenneth R Fisher | Chief Financial Officer | Buy | $21K (20,000 @ $1.03) |
| Apr 25, 2022 | Kenneth R Fisher | Chief Financial Officer | Buy | $20K (20,000 @ $0.99) |
| Mar 17, 2022 | Svetlana Dey | Director | Buy | $12K (10,000 @ $1.18) |
| Mar 17, 2022 | Douglas Clark Wurth | Director | Buy | $47K (40,000 @ $1.18) |
| Mar 17, 2022 | Gordon Winston Kinder | Chief Financial Officer | Buy | $3K (2,500 @ $1.16) |
| Mar 16, 2022 | Douglas Clark Wurth | Director | Buy | $65K (60,000 @ $1.09) |
| Mar 16, 2022 | Gordon Winston Kinder | Chief Financial Officer | Buy | $5K (5,000 @ $1.02) |
| Mar 15, 2022 | Gordon Winston Kinder | Chief Financial Officer | Buy | $455 (500 @ $0.91) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.